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of, respectively, 54.4 and 86.5 % with lower toxicity rates 
for focal salvage patients.
Conclusion Provisional data suggest that BDFS rates 
of focal salvage are in line with those of whole-gland 
approaches. There is evidence that focal salvage could 
decrease severe toxicity and preserve erectile function.
Keywords Prostate cancer · Radiorecurrent disease · 
Focal salvage · Iodine-125 brachytherapy · Cryotherapy · 
HIFU · Review
Introduction
Prostate cancer (PCa) patients primarily treated with exter-
nal beam radiotherapy (EBRT) or brachytherapy (BT) are 
at risk of a recurrence, depending on pretreatment char-
acteristics. Intermediate- and high-risk groups can suf-
fer from a biochemical recurrence in over 50 % of the 
cases after 10-year follow-up [1]. Subsequently, they are 
at risk of developing metastases and dying of PCa [2]. Up 
to 98 % of patients receive (palliative) androgen depriva-
tion therapy (ADT) as treatment after a biochemical recur-
rence [3]. However, a substantial amount of patients har-
bour organ-confined disease eligible for a curative salvage 
procedure [4, 5], thereby preventing exposure of patients 
to the often severe side effects of ADT [6]. Salvage nowa-
days is usually performed using a whole-gland approach, 
which is accompanied by a high chance of severe gastro-
intestinal (GI), genitourinary (GU) and erectile toxicity 
due to previous radiation damage to surrounding organs 
at risk [4, 5]. Given the evidence from pathology stud-
ies that recurrences are frequently localised at the site of 
the primary largest (index) tumour [7, 8], a focal salvage 
approach, directed solely at the area containing recurrent 
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Background/Aim Patients with locally recurrent prostate 
cancer after primary radiotherapy can be eligible for sal-
vage treatment. Whole-gland salvage techniques carry a 
high risk of toxicity. A focal salvage approach might reduce 
the risk of adverse events while maintaining cancer control 
in carefully selected patients. The aim of this review was to 
evaluate current literature to assess whether focal salvage 
leads to a comparable or favourable recurrence rate and less 
toxicity compared to whole-gland salvage.
Methods A literature search was performed using Pub-
Med, Embase and the Cochrane Library. A total of 3015 
articles were screened and assessed for quality. Eight 
papers [on focal cryoablation (n = 3), brachytherapy 
(n = 3) and high-intensity focused ultrasound (n = 2)] 
were used to report outcomes.
Results One-, 2-, 3- and 5-year biochemical disease-
free survival (BDFS) ranges for focal salvage are, respec-
tively, 69–100, 49–100, 50–91 and 46.5–54.5 %. Severe 
genitourinary, gastrointestinal and sexual function toxicity 
rates are 0–33.3 %. One study directly compares focal to 
whole-gland salvage cryotherapy, showing 5-year BDFS 
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tumour, might be a viable treatment option for patients 
with unifocal PCa recurrences without metastatic disease. 
This way, serious adverse events associated with whole-
gland salvage might be prevented, while cancer control is 
maintained. The current literature regarding biochemical 
disease free survival (BDFS) and functional outcomes of 
focal salvage techniques for prostate cancer recurrences 
after primary radiotherapy is evaluated here.
Materials and methods
Literature search
On 19 August 2015, a systematic literature search was 
performed in the PubMed, Embase and Cochrane Library 
databases. In order to create a sensitive search, the search 
syntax was build based on domain and determinant 
(Table 1). After removal of duplicates, 3015 papers were 
screened, selecting 55 articles with matching domain and 
determinant. Exclusion criteria are listed in the flow chart 
(Fig. 1). An additional reference search was performed, 
resulting in 12 studies for this review [9–20]. 
Study selection
Studies were subjected to a critical appraisal based on an 
adaptation of the Dutch Cochrane Centre recommenda-
tions (ACROBAT-NRSI risk of bias assessment tool) [21]. 
Studies were graded (+), (±) or (−) on relevance (domain, 
determinant, outcome) and validity (selection, study popu-
lation characteristics, exposure, primary outcome, second-
ary outcomes, follow-up and number of patients) [Table A1 
(supplementary file)].
All studies were observational cohorts or case series 
with either prospective or retrospective data acquisition. 
Therefore, no study could be considered of high quality. 
Blinding was applied in none of the studies (not graded). 
However, the primary outcome (BDFS) is unlikely to be 
influenced by information bias, due to the objectivity of the 
failure definition (Phoenix, i.e. PSA-nadir + 2.0 ng/ml). On 
the contrary, the toxicity assessment is subjective to infor-
mation bias and is graded in that way.
Confounding was not graded, since all studies except 
one were single-arm observational cohorts. The study by 
De Castro et al. [9] describes a two-armed cohort. Here, 
possible confounding factors are adequately described, but 
not corrected for in multivariable analysis.
Four studies describe case series ≤10 patients [12, 13, 
19, 20]. These were valued as low quality and excluded.
Table 1  Search syntax
All search terms (title/abstract) for PubMed, (ab,ti) for Embase and 
(:ti,ab,kw) for Cochrane
1 Salvage 14 Local
2 Therapy 15 Focal
3 Treatment 16 Prostate
4 Rescue 17 Prostatic
5 Cryoablation 18 Cancer
6 Cryosurgery 19 Carcinoma
7 Cryotherapy 20 Adenocarcinoma
8 Ablation 21 Neoplasma
9 Brachytherapy 22 Recurrence
10 HIFU 23 Recurrences
11 ‘high-intensity focused ultrasound’ 24 Recurrent
12 Hemi 25 Relapse
13 Partial 26 Radiorecurrent
27 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 
10 or 11
28 12 or 13 or 14 or 15
29 27 and 28
30 16 or 17 #34 Search Results
31 18 or 19 or 20 or 21 PubMed: 1719
32 22 or 23 or 24 or 25 or 26 Embase: 2811
33 30 and 31 and 32 Cochrane: 199
























Study protocol = 1
Guideline = 1
Technical report = 2
Reprinted article = 3
12
Inclusion criteria
Domain = locally 
recurrent Pca after 
primary radiotherapy




Fig. 1  Flow chart




A total of eight studies were eligible for data extraction, 
describing focal salvage treatment with cryoablation (CA) 
(n = 3) [9, 14, 16], low-dose-rate brachytherapy (LDR-BT) 
(n = 3) [15, 17, 18] and high-intensity focused ultrasound 
(HIFU) (n = 2) [10, 11] in 278 patients. Table 2 shows 
study characteristics. Studies used a salvage approach on 
a focal lesion (quadrant ablation by Ahmed et al. [10] and 
clinical target volume of approximately 17 % by Hsu et al. 
[15]), one half of the prostate (hemi) or a partial approach 
(area not specified by Li et al. [16] and Eisenberg et al. 
[14]). Nguyen et al. [17] describe LDR-BT to the entire 
peripheral zone. In all studies, ADT use was discontinued 
at time of enrolment.
Diagnosis of focality
All recurrences were initially detected by PSA meas-
urement (biochemical failure), verified with prostate 
biopsies. The diagnostic modalities used to determine 
the recurrence location differed. Available specifics are 
described here.
Five studies used magnetic resonance imaging (MRI). 
Ahmed et al. [10] describe the use of a multiparamet-
ric approach: T2-weighted (T2 W), diffusion-weighted 
(DW) and dynamic contrast-enhanced (DCE) 1.5-Tesla 
(T) MRI. Results were combined with transrectal ultra-
sound (TRUS)-guided or transperineal template prostate 
mapping (TPM) biopsies (n = 19 and n = 20, respec-
tively). Baco et al. [11] describe the use of T2 W, DW 
and DCE 3T MRI in 27 and T2 W and DW 1.5T MRI 
in 21 patients. Imaging results were verified a mean 15 
cores TRUS-guided biopsies (sd 10, range 7–60). Peters 
et al. [18] describe the use of T1 W, T2 W, DWI and DCE 
3T MRI, verified with systematic transrectal biopsies 
(median 10 cores, range 6–13). Sequences are not speci-
fied in the studies of Nguyen et al. [17] and Hsu et al. 
[15], though the latter did perform MR spectroscopy and 
acquired TRUS-guided biopsy confirmation of disease. 
Both do not define the amount of biopsy cores taken.
De Castro Abreu et al. [9] treated the tumour volume 
based on both systematic and lesion-targeted TRUS-guided 
biopsies and hypo-echogenic lesions on TRUS. Eisenberg 
et al. [14] treated based on 16-core sample TRUS-guided 
biopsy. Li et al. [16], using the Cryo On-Line Data (COLD) 
registry, do not describe any diagnostic modality used to 
define the location of the recurrence or (PSA-based) selec-
tion method.
Exclusion of metastatic disease
Three studies used positron emission tomography (PET) 
in excluding metastatic disease (Ahmed et al. [10], Baco 
et al. [11] and Peters et al. [18]). Ahmed et al. [10] used 
a combination of pelvic MRI, a radioisotope bone scan 
and 18-fluorodeoxyglucose (FDG) PET/CT in all patients 
for the assessment of metastatic disease (bone and lymph 
node). Baco et al. [11] used a combination of bone scan 
and pelvic CT or MRI. 11C-Choline PET was used in 27 of 
42 patients. Peters et al. also use a bone scan and pelvis CT 
or MRI, but used 18F-Choline PET in 10 of the 20 patients.
Biochemical disease‑free survival
Results on BDFS are also shown in Table 2. Biochemi-
cal failure was defined according to the Phoenix (PSA-
nadir + 2 ng/ml) or ASTRO definition (three consecutive 
post-nadir rises in PSA, with the moment of failure back-
dated between the nadir and the first rise). BDFS ranges 
at 1, 2, 3 and 5 years are, respectively, 69–100, 49–100, 
50–91 and 46.5–54.4 %. The studies with an MRI-based 
assessment of focal disease had BDFS of 49–100 % up to 
2–3 years compared to 72.4–79 % for non-MRI-based focal 
salvage series. The only 5-year Kaplan–Meier estimates 
come from the study by de Castro-Abreu et al. [9] and Li 
et al. [16], who do not use MRI for intraprostatic disease 
assessment or PET for exclusion of metastatic disease (de 
Castro-Abreu et al. [9]) or do not specify the assessment 
(Li et al. [16]). They provide BDFS of 46.5 % (Li et al. 
[16]) and 54.4 % (de Castro-Abreu et al. [9]).
Toxicity
Toxicity results are shown in Table 3 for various measure-
ment methods. CTCAE grades indicate (1) toxicity with-
out (the need for) intervention, (2) requiring medication, 
(3) requiring inpatient or outpatient surgical intervention, 
(4) requiring ICU admission and (5) death. No grade 4 or 
5 toxicity was reported. Higher IPSS (prostate symptoms), 
lower IIEF (erectile function) and lower QLQ C-30 (qual-
ity of life) indicate deterioration. In addition, Ahmed et al. 
[10] reported surgical complications according to the modi-
fied Clavien system, showing the need for intervention 
under local (grade 3a) or general (grade 3b) anaesthesia in, 
respectively, 1 (3 %) and 9 (23 %) patients. Nguyen et al. 
[17] reported outcomes according to the Radiation Therapy 
Oncology Group/Late Effects Normal Tissue Task Force 
criteria, showing rectal bleeding in 2 (8 %), urethral stric-
ture in 1 (4 %), periprostatic abscess in 1 (4 %) and pros-
tate–rectal fistula in 3 (12 %) patients.
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Both Hsu et al. [15] and Peters et al. [18] report no new 
≥grade 2 GI toxicity in the late phase (>3–6 months). 
Hsu et al. [15] report on five patients with ≥grade 2 GU 
toxicity requiring medication. Furthermore, two patients 
developed new medication-resistant erectile dysfunc-
tion (ED, grade 3) and two patients medication-respon-
sive ED. Peters et al. [18] report one patient (5 %) with 
a grade 3 urethral stricture, requiring endoscopic inci-
sion. One patients suffered from radiation cystitis grade 
2, managed with hyperbaric oxygen therapy. Five more 
patients had grade 2 urinary frequency, managed with 
medication. No new erectile dysfunction (ED) was seen 
in the five previously potent patients. Furthermore, a sig-
nificant decrease in the EORTC-PR25 urinary symptoms 
quality-of-life (QoL) domain after a median of 3 years 
was observed.
Functional deterioration was also observed in symptom 
scales used by Baco et al. [11] and Ahmed et al. [10]. An 
International Prostate Symptom Score (IPSS) increase from 
7.1 to 8.6 (p = 0.13) and 10.1 to 13 (no p value) was seen, 
respectively. Furthermore, International Index of Erectile 
Function (IIEF) decreased from mean 11.2 to 8 (p < 0.001) 
and median 18 to 13 (no p value), respectively. Baco et al. 
[11] do not notice a significant decrease in EORTC QLQ-
C30 score: 35.7–36.8 (p = 0.22).
Eisenberg et al. [14] describe the occurrence of one mild 
stress incontinence (grade not given), one urethral stricture 
requiring dilation and one prostatic urethral ulcer managed 
with suprapubic catheter drainage. Two out of five patients 
remained potent. Li et al. [16] describe 5 (5.5 %) patients 
requiring pad-use at 12 months and 3 (3.3 %) recto-urethral 
fistulas. Half of the patients retained potency, although 
medication was not specified.
A subdivision in more focally targeted ablation and 
studies using MRI-assessment for recurrences was not 
made due to (most importantly) the unavailability of sal-
vage extent.
Discussion
Comparing focal to whole‑gland salvage
The aim of this study was to assess whether focal salvage 
for local prostate cancer recurrences after primary radio-
therapy leads to a comparable or favourable recurrence 
rate and less toxicity compared to whole-gland salvage. 
De Castro Abreu et al. [9] present the only study com-
paring focal to whole-gland salvage cryotherapy. Recur-
rences were not verified by MR imaging. BF occurred in 
32 % (focal) and 12 % (whole-gland), resulting in 5-year 
Kaplan–Meier BDFS estimates of, respectively, 54.4 and 
86.5 %. This could be an indication that focal salvage 
patients are undertreated or that the relation is confounded 
Table 3  Toxicity
CTCAE Common Terminology Criterial for Adverse Events, GU genitourinary, GI gastrointestinal, SF sexual function, RTOG radiation therapy 
oncology group, IPSS International Prostate Symptoms Score, IIEF International Index of Erectile Function, QLQ C30 European Organisation 
for the Research and Treatment of Cancer Quality of Life Questionnaire, FU follow-up
Toxicity rates in numbers (%)
Questionnaire results: mean or a  median. Urethral toxicity: strictures, ulcers and recto-urethral fistulae formation
Study New CTCAE  
GU Toxicity grade ≥2
New CTCAE  
GI Toxicity grade ≥2
New CTCAE SF 
Toxicity grade ≥2
Hsu 4 (26.7) 0 (0) 4 (26.7)
Peters 6 (33.3) 0 (0) 0 (0)
Study New Clavien Toxicity grade ≥2 New late RTOG Toxicity grade ≥3
Ahmed 10 (30)
Nguyen 7 (28)
Study IPSS before/at last FU IIEF before/at last FU QLQ C-30 before/
at last FU
Ahmed 10.1/13 18/13a
Baco 7.1/8.6 11.2/7.0 35.7/36.8
Study New incontinence New urethral toxicity Potency before/after salvage
De Castro Abreu (focal vs. total) 0 versus 3 (0 vs. 12) 0 versus 1 (0 vs. 4) 7/2 versus 4/0 (28/8 vs. 16/0)
Eisenberg 1 (6.7) 2 (13.3)
Li 5 (5.5) 3 (3.3) 20/10 (21.2/11)
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by other factors related to BF. Since recurrences were not 
assessed by MRI or TPM biopsies, focal salvage patients 
might have been under assessed. Furthermore, the com-
parison indicates that focal salvage might be less toxic: no 
focal salvage patients developed incontinence or recto-ure-
thral fistula versus 3 and 1, respectively. Furthermore, two 
focal salvage patients retained potency, versus none in the 
total salvage group. However, these numbers were small 
and statistical significance was not achieved. This com-
parison between the two ablation methods is hampered 
by differences in primary radiation schedules/modali-
ties, the extend of focal salvage and differences in patient 
characteristics.
Whole-gland salvage outcomes are shown in Table 4. 
Systematic reviews on salvage therapies for radiorecurrent 
PCa [5, 22, 23] and the European Association of Urology 
(EAU) guideline [24] were searched to select the three larg-
est studies of the four common salvage therapies (salvage 
radical prostatectomy (SRP) [25–27], BT [28–30], CA 
[31–33] and HIFU [34–36]). These publications do not pro-
vide recommendations on the type of whole-gland salvage 
treatment to use.
Focal salvage BDFS rates (1, 2, 3, 5 years, respectively, 
69–100, 49–100, 50–72.4 and 46.5–54.4 %) are in line with 
BDFS outcomes reported for whole-gland salvage. The 
largest SRP and CA studies show 5-year freedom of failure 
survival (FFS) rates of, respectively, 48–58 and 54.5–56 %.
Notable results outside these ranges are reported by 
Spiess et al. [31], describing 450 whole-gland salvage 
CA patients, with 66 % failure after median follow-up of 
3.4 years. Grado et al. [29] describe 49 patients treated with 
BT, with a 5-year FFS of 34 %. Contrary to these results, 
Burri et al. [30] describe 37 patients treated with BT, with a 
5-year FFS of 64.5 %.
In addition to reported results, Wenske et al. [37] 
describe a cohort of 55 focal CA patients after primary 
radiotherapy (80 %) or CA (20 %). There is no stratifica-
tion for primary therapy. Reported 5-year BDFS (Phoenix 
definition) is 47 %. Bladder outlet obstruction occurred in 
1.8 % and fistula formation in 5.5 % of patients.
Toxicity of focal approaches is comparable to or favour-
able compared to whole-gland salvage. Fistula rates are 
low across all studies. Notable results are reported by Hsu 
et al. [15] describing 15 focal salvage BT patients. There 
was no new GI toxicity and no new incontinence. Potency 
(medication assisted) was preserved in 13/15. Peters et al. 
[18] report preserved potency in the five previously potent 
patients. Potency is sparsely reported in SRP cohorts. 
From the assessed reviews, two SRP studies were retrieved 
describing SF. Masterson et al. [38] report preserved (medi-




Biochemical recurrences in prostate cancer often seem to 
stem from a localised process. Data on the exact location 
are scarce, but it is suggested that the tumour often recurs at 
the site of the primary dominant or ‘index lesion’ [7, 8, 40, 
41]. The evidence is not unanimous, however, with tumour 
regrowth frequently occurring multifocally in some stud-
ies, although organ-confined and unifocal disease remains 
being observed [42, 43]. Also, radical prostatectomy or 
TPM biopsies are sometimes not used as the reference 
standard [7, 40], thereby possibly giving an overestima-
tion of local recurrences. The studies which use pathol-
ogy as the reference standard usually identify less unifo-
cal disease localisation [42, 43]. However, in these studies 
patients were often treated with lower doses of radiation 
than with current dose escalation. A recent large analysis 
by Zumsteg et al. [1] in which 2.694 patients were treated 
with IMRT with a total dose ≥79.2 Gy (maximal 85.6 Gy) 
shows that biochemical recurrences are still common. Esti-
mated 8-year recurrence rates of 9.7, 22.7 and 43.9 % for 
low, intermediate and high National Cancer Comprehen-
sive Network (NCCN) risk groups was observed. It might 
be that with these dose schedules, secondary tumour foci 
are increasingly successfully treated. This could mean that 
radiorecurrent disease is shifting towards the index lesion 
and theoretically more patients in the future can be eligible 
for focal salvage. In addition, even though cancer control 
rates are increasing with further dose escalation, ADT use 
and enhanced patient selection, there will be an increase in 
absolute numbers of patients with biochemical recurrent 
disease because more patients are primarily treated with 
radiotherapy. The stage migration to lower risk disease due 
to PSA screening could lead to more recurrences originat-
ing from increasingly lower risk disease, which is possibly 
more often localised and unifocal.
Study limitations
Reporting outcomes and comparing studies is significantly 
limited by several factors. The primary limitation is the 
lack of randomised controlled trials. All studies found are 
observational cohorts or case series. Selection of a more 
favourable or motivated patient population is a possibility 
in these focal salvage groups, thereby possibly biasing the 
comparison between focal and whole-gland salvage and 
between focal salvage modalities in terms of cancer control 
and toxicity. Furthermore, the lack of blinding in all studies 
could have biased especially toxicity assessment, both on 
patient and physician level.
1529World J Urol (2016) 34:1521–1531 
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Secondly, a straightforward comparison of studies is 
difficult. There is no international consensus on the defini-
tion of failure. Although there is a tendency to report BDFS 
according to the Phoenix definition (used in all focal sal-
vage studies), there is a wide variety of failure definitions, 
including combined biochemical and clinical (physical, 
radiological, histopathological) proof of disease. Gelet 
et al. [35] report a 73 % negative biopsy rate at 30 months; 
however, combining biopsy results with biochemical results 
and need for ADT, the disease-free rate drops to 38 %. In 
reporting toxicity outcomes, there is little consistency as 
well.
In addition, diagnostic modalities for the assessment 
of recurrences and the exclusion of metastases vary. Only 
Ahmed et al. [10], Peters et al. [18] and Baco et al. [11] 
use PET in all, 10 and 27 patients, respectively, to exclude 
metastatic disease. PET has increased accuracy in assess-
ing lymph node and distant metastases over technetium-99 
scintigraphy and/or CT/MRI [44–46]. This could have 
contributed to more favourable outcomes in terms of can-
cer control and could possibly lead to a further increase in 
the future if these modalities become the diagnostic stand-
ard. Also, new biopsy techniques could lead to a further 
increase in the assessment of a focal recurrence, without 
missing possible significant multifocal recurrent disease. 
TPM biopsies could lead to increased accuracy over sys-
tematic TRUS-guided biopsies alone, while MRI-guided 
biopsies might decrease the detection of insignificant dis-
ease further [47, 48]. However, TPM biopsies were only 
adopted by Ahmed et al. [10], and MRI-guided biopsies 
by Baco et al. [11]. The other studies used different TRUS-
guided schedules, thereby possibly undertreating the pros-
tate with a focal salvage approach.
Finally, study populations are relatively small, limiting 
power, and follow-up is relatively short, limiting the num-
ber of outcome events and thereby an accurate estimation 
of BDFS proportions and late toxicity.
Future trials
When considering trials for salvage modalities, willingness 
for randomisation is essential. This has been extremely 
problematic in a randomised study comparing prostatec-
tomy and brachytherapy [49]. This accrual problem was 
also present in the PIVOT trial, in which only 15 % of 
patients were randomised [50]. Increasing favourable data 
from focal salvage studies (e.g. from the recently started 
FORECAST trial [Focal Recurrent Assessment and Sal-
vage Treatment for Radiorecurrent Prostate Cancer] [51]) 
might further decrease the willingness for randomisation in 
potential future head to head salvage trials.
A solution can possibly be found in the cohort multiple 
randomised controlled trial (cmRCT) design [52]. In this 
study design, all patients with radiorecurrent disease (or all 
prostate cancer patients) in a centre would be included into 
a cohort. With consent, these patients can in the future be 
randomised into experimental and control groups when a 
new treatment becomes available, providing the standard 
of care to the control group and, after additional consent, 
a new modality to the experimental group. This could pro-
vide unbiased comparisons between salvage procedures 
and possibly even between salvage ablation modalities, 
without the need for substantial resources to achieve suf-
ficient accrual.
Conclusion
In this review of studies on focal salvage therapies, pro-
visional data suggest that BDFS rates after focal salvage 
are in line with those of whole-gland approaches. There 
is evidence that focal salvage could decrease severe toxic-
ity and preserve erectile function. Based on these results, 
focal salvage can be considered a viable option for unifo-
cal prostate cancer recurrences after primary radiotherapy 
in properly selected patients. For further research, there is 
a great need for randomised controlled trials comparing 
salvage ablation methods and possibly even modalities. 
These trials would need to be uniform regarding patient 
selection and in outcome assessment and reporting. Lastly, 
relevant endpoint (mortality) assessed after sufficient 
follow-up are preferred over proxy outcomes such as bio-
chemical failure.
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